Global Bacterial Conjunctivitis Drugs Market 2016-2020

Global Bacterial Conjunctivitis Drugs Market 2016-2020

Category : Pharmaceuticals
Published On : February  2016
Pages : 57

request-discount


TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com
About Bacterial Conjunctivitis Drugs

Bacterial conjunctivitis, which affects either one or both the eyes, is an extremely contagious eye condition wherein the conjunctiva is infected. Staphylococci, streptococci, gonococci, and Chlamydia are some of the causative agents of bacterial conjunctivitis. Extremely pathogenic bacteria such as Chlamydia trachomatis and Neisseria gonorrhea cause severe bacterial conjunctivitis. Antibiotics help in eradicating the microbes, resulting in faster clearance of the symptoms. Broad-spectrum antibiotics such as Besivance, Zymaxid, Maxitrol, and AzaSite, in the form of antibiotic pills, ointment, or eye drops help treat the infection. Fluoroquinolones, macrolides, aminoglycosides, and phenicols are among the different classes of antibiotics that are commonly prescribed to treat the condition.

Technavios analysts forecast the global bacterial conjunctivitis drugs market to grow at a CAGR of 2.77% during the period 2016-2020.

Covered in this report 
The report covers the present scenario and the growth prospects of the global bacterial conjunctivitis drugs market for 2015-2020. To calculate the market size, it considers revenue generated from the sales of branded and generic drugs along with over-the-counter (OTC) drugs used to treat bacterial conjunctivitis.

The market is divided into the following segments based on geography: 
Americas
APAC 
EMEA

Technavios report, Global Bacterial Conjunctivitis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
Akorn
Alcon
Allergan
Bausch & Lomb 

Other prominent vendors 
Bayer
Daiichi Sankyo
F. Hoffmann-La Roche
InSite Vision
Merck
Nicox
Novartis
Perrigo 
Pfizer
Santen Pharmaceutical
Shire
Valeant Pharmaceuticals

Market driver 
Rising awareness about infections
For a full, detailed list, view our report 

Market challenge 
Patent expiry of drugs
For a full, detailed list, view our report 

Market trend 
Patient assistance programs
For a full, detailed list, view our report 

Key questions answered in this report 
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors? 

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Overview: Bacterial conjunctivitis
Conjunctivitis
Bacterial conjunctivitis
Signs and symptoms
Diagnosis
Management
Economic burden

PART 06: Pipeline analysis
FST-100
AzaSite Xtra (ISV-405)

PART 07: Antimicrobial resistance
Initiatives to improve innovation of antibiotics

PART 08: Legislation relating to antibiotic use in US

PART 09: Market landscape
Market overview
Market size and forecast
Bacterial conjunctivitis drugs market in US
Five forces analysis

PART 10: Market segmentation by drug class
Fluoroquinolones
Aminoglycosides
Macrolides
Other

PART 11: Geographical segmentation
Global bacterial conjunctivitis drugs market by geography 2015-2020
Bacterial conjunctivitis drugs market in Americas
Bacterial conjunctivitis drugs market in EMEA
Bacterial conjunctivitis drugs market in APAC

PART 12: Market drivers
Rising awareness about infection
Development of multidrug-resistant variants
Prevalence of bacterial conjunctivitis

PART 13: Impact of drivers

PART 14: Market challenges
Patent expiry of drugs
Contentment with existing therapies
Adverse effects and limited efficacy of drugs
Weak R&D of drugs

PART 15: Impact of drivers and challenges

PART 16: Market trends
Strategic alliances and M&A
Use of combination therapies
Patient assistance programs

PART 17: Vendor landscape
Competitive scenario
Akorn
Alcon
Allergan
Bausch & Lomb
Other prominent vendors

PART 18: Appendix
List of abbreviations

PART 19: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Types of conjunctivitis
Exhibit 03: Types of bacterial conjunctivitis
Exhibit 04: Signs and symptoms of bacterial conjunctivitis
Exhibit 05: Drugs used to treat conjunctivitis
Exhibit 06: Global bacterial conjunctivitis drugs market: Pipeline portfolio
Exhibit 07: Causes of antimicrobial resistance
Exhibit 08: Initiatives improving antibiotic innovation
Exhibit 09: Legislation relating to antibiotic use in US
Exhibit 10: Global bacterial conjunctivitis drugs market 2015-2020 ($ billions)
Exhibit 11: Snapshot of global bacterial conjunctivitis drugs market
Exhibit 12: Percentage share of bacterial conjunctivitis drugs market in US
Exhibit 13: Bacterial conjunctivitis drugs market in US 2015-2020 ($ millions)
Exhibit 14: Five forces analysis
Exhibit 15: Global bacterial conjunctivitis drugs market by drug class
Exhibit 16: Global bacterial conjunctivitis drugs market by geography 2015
Exhibit 17: Global bacterial conjunctivitis drugs market by geography 2015-2020 ($ billions)
Exhibit 18: Bacterial conjunctivitis drugs market in Americas 2015-2020 ($ millions)
Exhibit 19: Bacterial conjunctivitis drugs market in EMEA 2015-2020 ($ millions)
Exhibit 20: Bacterial conjunctivitis drugs market in APAC 2015-2020 ($ millions)
Exhibit 21: Global bacterial conjunctivitis drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 22: Key drivers
Exhibit 23: Impact of drivers
Exhibit 24: Key challenges
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Key trends
Exhibit 27: Akorn: YoY growth and revenues in ophthalmic segment 2011-2013 ($ millions)
Exhibit 28: Akorn: Key takeaways
Exhibit 29: Business segmentation by revenue 2014
Exhibit 30: Alcon: YoY growth and revenue generated from sales of ophthalmic products 2011-2014 ($ billions)
Exhibit 31: Alcon: Key takeaways
Exhibit 32: Allergan: Key takeaways
Exhibit 33: Bausch & Lomb: Key takeaways

Enquiry Before Buy